GlassScriptPhysician profile
Erica E Schneider
NPI 1659646990
$3,520.07
in general payments reported to CMS, 2019-2025
37 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $1,139 · 2021: $53.77 · 2022: $13.59 · 2023: $41.43 · 2024: $178 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $667.34 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $513.61 | 2019-2025 | Fasenra, Airsupra, Tagrisso |
| Philips North America LLC | $255.18 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $168.21 | 2019 | |
| Grifols USA, LLC | $160.05 | 2019-2020 | |
| Amgen INC. | $153.43 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $146.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.29 | 2019-2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $116.30 | 2019-2020 | |
| Genentech USA, INC. | $97.71 | 2019-2020 | |
| Electromed, INC. | $92.15 | 2019-2025 | Smartvest |
| Genzyme Corporation | $86.71 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $82.88 | 2019-2025 | Dupixent |
| Pfizer INC. | $76.70 | 2020-2025 | |
| Mylan Specialty L.P. | $74.16 | 2019-2024 | Yupelri |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $60.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.73 | 2020-2025 | Glassia |
| Pulmonx Corporation | $51.86 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Advanced Respiratory, INC | $50.00 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $48.41 | 2020 | |
| Boston Scientific Corporation | $39.72 | 2024 | Ekosonic |
| Celgene Corporation | $38.70 | 2019 | |
| Resmed Corp | $38.19 | 2019 | |
| Circassia INC. | $35.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $35.23 | 2019 | |
| Lilly USA, LLC | $35.21 | 2019-2020 | |
| Melinta Therapeutics, LLC | $31.47 | 2025 | Rezzayo |
| Abbvie INC. | $24.35 | 2023 | Avycaz |
| Abbott Laboratories | $22.62 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.59 | 2024 | Nuzyra |
| Zoll Circulation INC | $17.08 | 2023 | Catheter, Temperature Management System Start-Up Kit, Temperature Management System |
| Allergan, INC. | $16.33 | 2019 | |
| Optinose US, INC. | $15.97 | 2020 | |
| Gilead Sciences, INC. | $15.51 | 2019 | |
| Shire North American Group INC | $15.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.59 | 2022 | |
| Harmony Biosciences LLC | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.